Renal hypertrophy and kidney disease in diabetes

Diabetes/Metabolism Reviews

Volumn 12, Issue 3, 1996, Pages 217-241

  Rabkin, Ralph ^a,c   Fervenza, Fernando C ^b  

^a Vet Aff Palo Alto Hlth Care Syst ^*  (United States)

^b STANFORD UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIABETES MELLITUS; DIABETIC NEPHROPATHY; HUMAN; KIDNEY HYPERTROPHY; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW;

ANIMALS; DIABETIC NEPHROPATHIES; HUMANS; HYPERTROPHY; KIDNEY;

EID: 0029840510     PISSN: 07424221     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0895(199610)12:3<217::AID-DMR165>3.0.CO;2-C     Document Type: Review

References (269)

1. United States Renal Data System: Annual Data Report. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, 1994, p. 1.
2. Diabetes Control and Complications (DCCT) Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 47: 1703-1720, 1995.
3. Zeller K, Whittaker E, Sullivan L, Raskin P, and Jacobson HR: Effect of restricting dietary protein on the progression of renal failure in patient with insulin-dependent diabetes mellitus. N Engl J Med 324: 78-84, 1991.
4. Lewis EJ, Hunsicker LG, Bain RP, and Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1466, 1993.
5. Selby JV, Fitzsimmons SC, Newman JM, Katz PP, Sepe S, and Showstack J: The natural history and epidemiology of diabetic nephropathy. Implications for prevention and control. JAMA 263: 1954-1960, 1990.
6. Hostetter TH: Diabetic nephropathy: metabolic versus hemodynamic considerations. Diabetes Care 15: 1205-1215, 1992.
7. Zatz R, Meyer TW, Rennke HG, and Brenner BM: Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 82: 5963-5967, 1985.
8. Striker GE, Peten EP, Carome MA, Pesce CM, Schmidt K, Yang C-W, Elliot SJ, and Striker LJ: The kidney disease of diabetes mellitus: a cell and molecular biology approach. Diabetes/ Metabolism Reviews 9: 37-56, 1993.
9. Hostetter TH: Mechanisms of diabetic nephropathy. Am J Kidney Dis 23: 188-192, 1994.
10. DeRubertis FK, and Craven PA: Activation of protein kinase C in glomerular cells in diabetes: mechanisms and potential links to the pathogenesis of diabetic glomerulopathy. Diabetes 43: 1-8, 1994.
11. Frank RN: The aldose reductase controversy. Diabetes 43: 169-172, 1994.
12. King GL, Shiba T, Oliver J, Inoguchi T, and Bursel S-E: Cellular and molecular abnormalities in the vascular endothelium of diabetes mellitus. Annu Rev Med 45: 179-188, 1994.
13. Morgensen CE, and Andersen MJ: Increased kidney size and glomerular filtration rate in early juvenile diabetes. Diabetes 22: 706-712, 1973.
14. Garcia PJ, Mateos AF, Grande C, Pallardo LF, Arnalich F, Gil A, Vazquez JJ, and Montero GA: Relation of kidney size to kidney function in early insulin-dependent diabetes. Diabetologia 21: 363-367, 1981.
15. Mogensen CE, and Andersen MJF: Increased kidney size and glomerular filtration rate in untreated juvenile diabetes: normalization by insulin-treatment. Diabetologia 11: 221-224, 1975.
16. Shechter P, Bonner G, and Rabkin R: Tubular cell protein degradation in early diabetic renal hypertrophy. J Am Soc Nephrol 4: 1582-1587, 1994.
17. Seyer-Hansen K: Renal hypertrophy in streptozotocin-diabetic rats: Clin Sci Mol Med 51: 551-555, 1976.
18. Seyer-Hansen K: Renal hypertrophy in experimental diabetes mellitus. Kidney Int 23: 643-646, 1983.
19. Cortes P, Dumler F, Goldman J, and Levin NW: Relationship between renal function and metabolic alterations in early streptozocin-induced diabetes in rats. Diabetes 36: 80-87, 1987.
20. Meyer-Schwickerath R, Pfeiffer A, Blum WF, Freyberger H, Klein M, Lösche C, Röllmann R, and Schwartz H: Vitreous levels of the insulinlike growth factors I and II, and the insulinlike growth factor binding proteins 2 and 3, increase in neovascular eye disease. J Clin Invest 92: 2620-2625, 1993.
21. +-ATPase activity after insulin treatment in streptozotocin-diabetic rats. Endocrinology 120: 2166-2173, 1987.
22. Tuttle KR, Burton JL, Perusek MC, Lancaster JL, Kopp DT, and DeFronzo RA: Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med 324: 1626-1632, 1991.
23. Morgensen CE, and Anderson MJF: Increased kidney size and glomerular filtration rate in untreated juvenile diabetes: normalization by insulin-treatment. Diabetologia 11: 221-224, 1975.
24. Christiansen JS, Gammelgaard J, Tronier B, Svendsen PA, and Parving H-H: Kidney function and size in diabetes before and during initial insulin treatment. Kidney Int 21: 683-688, 1982.
25. Christiansen J, Gammelgaard J, Frandsen M, and Parving HH: Increased kidney size, glomerular filtration rate and renal plasma flow in short-term insulin-dependent diabetes. Diabetologia 20: 451-156, 1981.
26. Wiseman MJ, Saunders AJ, Keen H, and Viberti GC: Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes. N Engl J Med 312: 617-621, 1985.
27. Rasch R, and Rytter Norgaard JO: Renal enlargement: comparative autoradiographic studies of 3H-thymidine uptake in diabetic and uninephrectomized rats. Diabetologia 25: 280-287, 1983.
28. Butcher D, Kikkawa R, Klein L, and Miller M: Size and weight of glomeruli isolated from human diabetic and non diabetic kidneys. J Lab Clin Med 89: 544-553, 1977.
29. Seyer-Hansen K, Hansen J, and Gunderson HJG: Renal hypertrophy in experimental diabetes: a morphometric study. Diabetologia 18: 501-505, 1980.
30. Østerby R, and Gundersen HJG: Fast accumulation of basement membrane material and the rate of morphological changes in acute experimental diabetic glomerular hypertrophy. Diabetologia 18: 493-500, 1980.
31. Cohen MP, and Klein CV: Glomerulopathy in rats with streptozotocin diabetes. Accumulation of glomerular basement membrane analogous to human diabetic nephropathy. J Exp Med 149: 623-631, 1979.
32. Hostetter TH, Troy JL, and Brenner BM: Glomerular hemodynamics in experimental diabetes. Kidney Int 19: 410-415, 1981.
33. Mauer SM: Structural-functional correlations of diabetic nephropathy. Kidney Int 45: 612-622, 1994.
34. Mauer SM, Lane P, Zhu D, Fioretto P, and Steffes MW: Renal structure and function in insulin-dependent diabetes mellitus in man. J Hypertens 10: S17-S20, 1992.
35. Østerby R: Renal pathology in diabetes mellitus. Curr Opinions Nephrol Hypertens 2: 475-483, 1993.
36. Gundersen HJG, Mogensen CE, Seyer-Hansen K, Osterby R, and Lundbaek K: Early and late changes in the diabetic kidney. Adv Nephrol Necker Hosp 8: 43-62, 1979.
37. Nakamura T, Fuku MI, Ebihara I, Osada S, Nagaoka I, Tomino Y, and Koide H: mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 42: 450-456, 1993.
38. Rabkin R, Dahl DC, Mahoney CA, and Tsao T: Protein catabolism in cultured kidney cells. Kidney Int 36: S11-S14, 1989.
39. Peterson DT, Green WC, and Reaven GM: Effect of experimental diabetes mellitus on kidney ribosomal protein synthesis. Diabetes 20: 649-654, 1971.
40. Takano Y, Minami H, Misake A, Nakabou Y, and Hagihira H: A possible role for ribonuclease in the regulation of protein synthesis in relation to kidney growth of diabetic rat. Tokushima J Exp Med 26: 5-12, 1979.
41. Garlick PJ, Albertse EC, NcNurlan MA, and Pain VM: Protein turnover in tissues of diabetic rats. Acta Biol Med Germ 40: 1301-1307, 1981.
42. Mortimore GE, and Poso AR: Intracellular protein catabolism and its control during nutrient deprivation and supply. Annu Rev Nutr 7: 539-564, 1987.
43. Rabkin R, and Dahl DC: Factors controlling intracellular protein turnover in the kidney. Semin Nephrol 10: 472-480, 1990.
44. de Almeida Barbosa A Jr, Zhou H, Hultenschmidt D, Totovic V, Jurilj N, and Pfeifer U: Inhibition of cellular autophagy in proximal tubular cells of the kidney in streptozotocindiabetic and uninephrectomized rats. Virchows Arch Biol Cell Pathol 61: 359-366, 1992.
45. Han K, Lehringer-Polzin M, Zhou H, and Pfeifer U: Cellular autophagy in proximal tubules of early diabetic rats following insulin treatment of islet transplantatin. Virchows Arch Biol Cell Pathol 61: 367-373, 1992.
46. Pfeifer V, and Warmuth-Metz M: Inhibition by insulin of cellular autophagy in proximal tubular cells of rat kidney. Am J Physiol 244: E109-E114, 1983.
47. Belfiore F, Rabuazzo AM, Iannello S, Campione R, and Vasta D: Cathepsin D and other hydrolases in the kidney of streptozotocin-diabetic mice: possible relevance to microangiopathy. Horm Metab Res 17: 435-437, 1985.
48. Nerurkar IA, Satav JG, and Katyare SS: Insulin-dependent changes in lysosomal cathepsin D activity in rat liver, kidney, brain and heart. Diabetologia 31: 119-122, 1988.
49. Olbricht CJ, and Geissinger B: Renal hypertrophy in streptozotocin diabetic rats: role of proteolytic lysosomal enzymes. Kidney Int 41: 966-972, 1992.
50. Schaefer L, Schaefer RM, Ling H, Teschner M, and Heidland A: Renal proteinases and kidney hypertrophy in experimental diabetes. Diabetologia 37: 567-571, 1994.
51. Fushimi H, and Tarui S: β-Glucosidases and diabetic microangiopathy. J Biochem 79: 265-270, 1976.
52. Tsao TC, Shi JD, Mortimore GE, Gragoe EJ Jr, and Rabkin R: Modulation of kidney cell protein degradation by insulin. J Lab Clin Med 116: 369-376, 1990.
53. Pain VM, Albertse EC, and Garlick PJ: Protein metabolism in skeletal muscle, diaphragm and heart of diabetic rats. Am J Physiol 245: E604-E610, 1983.
54. Schwieger J, and Fine LG: Renal hypertrophy, growth factors and nephropathy in diabetes mellitus. Semin Nephrol 10: 242-253, 1990.
55. Bondy CA, Underwood LE, Clemmons DR, Guler H-P, Bach MA, and Skarulis M: Clinical uses of insulin-like growth factor I. Ann Intern Med 120: 593-601, 1994.
56. Flyvbjerg A, Thorlacius-Ussing O, Naeraa R, Igerslev J, and Ørskov H: Kidney tissue somatomedin C and initial renal growth in diabetic and uninephrectomized rats. Diabetologia 31: 310-314, 1988.
57. Rabkin R, Tsao T, Shi J, and Mortimer G: Amino acids regulate kidney cell protein breakdown. J Lab Clin Med 11: 505-513, 1991.
58. Olgemöller B, and Schleicher E: Alterations of glomerular matrix proteins in the pathogenesis of diabetic nephropathy. Clin Invest 71: S13-519, 1993.
59. Alder S: Structure-function relationships associated with extracellular matrix alterations in diabetic glomerulopathy. J Am Soc Nephrol 5: 1165-1172, 1994.
60. Ziyadeh FN: Renal tubular basement membrane and collagen type IV in diabetes mellitus. Kidney Int 43: 114-120, 1993.
61. Romen W, Lang H, Hemel R, and Heck T: Studies on collagen metabolism in rats, II. Turnover and amino acid composition of the collagen of glomerular basement membrane in diabetes mellitus. Virchows Arch Cell Pathol 36: 313-320, 1982.
62. Falk RJ, Scheinman JI, Mauer SM, and Michael AF: Polyantigenic expansion of basement membrane constituents in diabetic nephropathy. Diabetes 32: 34-39, 1983.
63. Shimomura H, and Spiro RG: Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes: decreased levels of heparan sulfate proteoglycan and laminin. Diabetes 36: 374-381, 1982.
64. Reckelhoff JF, Tygart VL, Mitias MM, and Walcott JL: STZ-induced diabetes results in decreased activity of glomerular cathepsin and metalloprotease in rats. Diabetes 42: 1425-1432, 1993.
65. Lubec G, Leban J, Peyroux J, Strenberg M, Pollak A, Latzka U, and Coradello H: Reduced collagenolytic activity of rat kidneys with strepotozotocin diabetes. Nephron 30: 357-360, 1982.
66. Ziyadeh FN: The extracellular matrix in diabetic nephropathy. Am J Kidney Dis 22: 736-744, 1993.
67. Cohen MF, Surma ML, and Wu V-Y: In vivo biosynthesis and turnover of glomerular basement membrane in diabetic rats. Am J Physiol 242: F385-F389, 1982.
68. Nakamura T, Takahashi T, Fukui M, Ebihara I, Osada S, Tomino Y, and Koide H: Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats. J Am Soc Nephrol 5: 1492-1497, 1995.
69. Nakamura T, Fukui M, Ebihara I, Osada S, Tomino Y, and Koide H: Abnormal gene expression of matrix metalloproteinases and their inhibitor in glomeruli from diabetic rats. Renal Physiol Biochem 17: 316-325, 1994.
70. Fukui M, Nakamura T, Ebihara I, Shirato I, Tomino Y, and Koide H: ECM gene expression and its modulation by insulin in diabetic rats. Diabetes 41: 1520-1527, 1992.
71. Kitamura M, Kitamura A, Mitarai T, Maruyama N, Nagasawa R, Kawamura T, Yoshida H, Takahashi T, and Sakai O: Gene expression of metalloproteinase and its inhibitor in mesangial cells exposed to high glucose. Biochem Biophys Res Commun 185: 1055-1061, 1992.
72. Border WA, and Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 331: 1286-1292, 1994.
73. Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46: 223-234, 1995.
74. Vlassara H, Bucala R, and Striker L: Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implication for diabetes and aging. Lab Invest 70: 138-151, 1994.
75. Vlassara H: Recent progress on the biologic and clinical significance of advanced glycosylation end products. J Lab Clin Med 124: 19-30, 1994.
76. Schmidt AM, Mora R, Cao K, Yan SD, Brett J, Ramakrishnan R, Tsang TC, Simionescu M, and Stern D: The endothelial cell binding site for advanced glycation end product consists of a complex: and integral membrane protein and a lactoferrin-like polypeptide. J Biol Chem 269: 9882-9888, 1994.
77. Vlassara H, Brownlee M, and Cerami A: High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci USA 82: 5588-5592, 1985.
78. Doi T, Vlassara H, Kirstein M, Yamada Y, Striker GE, and Striker LJ: Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci 89: 2873-2877, 1992.
79. Skolnick EY, Yang Z, and Makita Z: Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tis- sue remodelling and diabetic nephropathy. J Exp Med 174: 931-939, 1991.
80. Yang CW, Vlassara H, Peten EP, He C-J, Striker GE, and Striker LJ: Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 91: 9436-9440, 1994.
81. Throckmorton DC, Brogden AP, Min, Rasmussen H, and Kashgarian M: PDGF and TFGβ1 mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int 48: 111-117, 1995.
82. Mullokandov EA, Franklin WA, and Brownlee M: DNA damage by the glycation products of glyceraldehyde-3-phosphate and lysine. Diabetologia 37: 145-149, 1994.
83. Giardino I, Edelstein D, and Brownlee M: Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity: a model for intracellular glycosylation in diabetes. J Clin Invest 94: 110-117, 1994.
84. Kashgarian M, Oshima S, Takeuchi A, Throckmorton D, and Rasmussen H: The contribution of mesangial cell collagen synthesis to the pathogenesis of diabetic nephropathy. Contrib Nephrol 107: 132-139, 1994.
85. Kreisberg JI, and Ayo DH: The glomerular mesangium in diabetes mellitus. Kidney Int 43: 109-113, 1993.
86. Cohen MP, and Khalifa A: Renal glomerular collagen synthesis in streptozotocin diabetes. Biochim Biophys Acta 500: 395-404, 1977.
87. Cohen MP, Dasmahapatra A, and Wu V-Y: Deposition of basement membrane in vitro by normal and diabetic rat renal glomeruli. Nephron 27: 146-151, 1981.
88. Brownlee M, and Spiro RG: Glomerular basement membrane metabolism in the diabetic rat. Diabetes 28: 121-125, 1979.
89. Beisswenger PJ: Glomerular basement membrane: biosynthesis and chemical composition in the streptozotocin diabetic rat. J Clin Invest 58: 844, 1976.
90. Poulsom R, Kurkinen M, Prockop DJ, and Boot-Hanford RP: Increased steady-state levels of laminin B1 mRNA in kidneys of long-term streptozotocin-diabetic rats. J Biol Chem 263: 10072-10076, 1988.
91. Abrass CK: Diabetic nephropathy: mechanisms of mesangial matrix expansion. West J Med 162: 318-321, 1995.
92. Striker LJ, Peten EP, Elliot SJ, Doi T, and Striker GE: Mesangial cell turnover: effect of heparin and peptide growth factors. Lab Invest 64: 446-456, 1991.
93. Clemmons DR, Jones JI, Busby WH, and Wright G: Role of insulin-like growth factor binding proteins in modifying IGF actions. Ann NY Acad Sci 692: 10-21, 1993.
94. Abrass C, Zawadzki I, and Raugi G: Insulin and IGF I and growth hormone treatment of cultured rat mesangial cells is associated with changes in mRNA expression for collagen I, III and IV. J Am Soc Nephrol 2: 570-572, 1991.
95. Ziyadeh FN, and Goldfarb S: The renal inters titium in diabetes mellitus. Kidney Int 39: 464-475, 1991.
96. Bader R, Bader H, Grund KE, Mackensen-Heah S, Christ S, and Bohle A: Structure and function of the kidney in diabetic glomerulosclerosis: correlations between morphologic and functional parameters. Pathol Res Pract 167: 204-216, 1980.
97. Mauer SM, Steffes MW, Ellis EN, Sutherland DER, Brown DM, and Goetz EC: Structural-functional relationships in diabetic nephropathy. J Clin Invest 74: 1143-1155, 1984.
98. Ziyadeh FN, Goldfarb S, and Kern EFO: Diabetic nephropathy: metabolic and biochemical mechanisms. In Contemporary Issues in Nephrology, Vol 20: The Kidney and Diabetes Mellitus, Brenner BM, and Stein JH (Eds). Churchill Livingstone, New York, 1989, pp 87-113.
99. Kleinman KS, and Fine LG: Prognostic implications of renal hypertrophy in diabetes mellitus. Diabetes Metab Rev 4: 179-189, 1988.
100. Ong ACM, and Fine LG: Tubular-derived growth factors and cytokines in the pathogenesis of tubulointerstitial fibrosis: implications for human renal disease progression. Am J Kidney Dis 23: 205-209, 1994.
101. Petersen J, Ross J, and Rabkin R: Effect of insulin therapy on established diabetic nephropathy in rats. Diabetes 37: 1346-1350, 1988.
102. Poulsen JE: Houssay phenomenon in man: recovery from retinopathy in case of diabetes with Simond's disease. Diabetes 2: 7-12, 1953.
103. Sönksen PH, Russell-Jones D, and Jones RH: Growth hormone and diabetes mellitus. Horm Res 40: 68-79, 1993.
104. Sharp PS, and Johnston DG: Growth hormone and the microvascular complications of diabetes. Trends in Endocrenology and Metabolism 315-318, 1990.
105. Lundbaek K, Christensen NJ, Jensen VA, Johansen K, Olsen TS, Prang Hansen A, Ørskov H, and Østerby R: Diabetes, diabetic angiopathy and growth hormone. Lancet ii: 131-133, 1970.
106. Poulsen JE: Diabetes and anterior pituitary insufficiency: final course and post mortem study of a diabetic patient with Sheehan's syndrome. Diabetes 15: 73-77, 1976.
107. Flyvbjerg A, Landau D, Domene H, Hernandez L, and LeRoith D: The role of growth hormone, insulin-like growth factors (IGFs) and IGF-binding proteins in experimental diabetic kidney disease. Metabolism 1995, 44: 67-71.
108. Marshall SM, and Alberti KGMM: Alterations in the growth hormone/insulin-like growth factor I axis in human and experimental diabetes: differences and similarities. In Growth Hormone and Insulin-like Growth Factor I, Flyvbjerg A, Orskov H, and Alberti KGMM (Eds). Wiley, Chichester, 1993, pp 23-45.
109. Tamborlane WV, Hintz RL, Bergman M, Genel M, Felig P, and Sherwin RS: Insulin infusion pump treatment of diabetes. N Engl J Med 305: 303-305, 1981.
110. Kjeldsen H, Hansen AP, and Lundbaek K: Twenty four hour serum growth hormone levels in maturity onset diabetes. Diabetes 24: 977-982, 1975.
111. Flyvbjerg A: Growth factors and diabetic complications. Diabetic Med 7: 387-399, 1990.
112. Hammerman MR, and Miler SB: The growth hormone insulin-like growth factor axis in kidney revisited. Am J Physiol 265: F1-F14, 1993.
113. O'Shea MH, and Lyish DT: Growth hormone and the kidney: a case presentation and review of the literature. J Am Soc Nephrol 3: 157-161, 1992.
114. Blankenship PJ, Derkx FHM, Birkenhäger JC, Lamberts SWJ, Mulder P, Verschoor L, Schalekamp MADH, and Weber RFA: Glomerular hyperfiltration in insulin-dependent diabetes mellitus is correlated with enhanced growth hormone secretion. J Clin Endocrinol Metabol 77: 498-502, 1993.
115. Newbold KM, Howie AJ, Girling AJ, Kizaki T, Bryan RL, and Carey MP: A simple method for assessment of glomerular size and its use in the study of kidneys in acromegaly and compensatory renal enlargement. J Pathol 158: 139-146, 1989.
116. Pedersen MM, Christensen SE, Christiansen JS, Pedersen EB, Morgensen CE, and Ørskov H: Acute effects of a somatostatin analogue on kidney function in type 1 diabetic patients. Diabetic Med 7: 304-309, 1990.
117. Serri O, Beauregard H, Brazeau P, Abribat T, Lanbert J, Harris A, and Vachon L: Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulindependent diabetes. JAMA 265: 888-892, 1991.
118. Stegeman CA, Dullaart RPF, Meijer S, Marbach P, and Sluiter WJ: Acute renal effects of somatostatin analogue, octreotide, in insulin-dependent diabetic patients: antagonism by low dose glucagon. Diab Nutr Metab 6: 87-95, 1993.
119. 118a.Muchaneta-Kubara EC, Sayed-Ahmed N, Besbas N, Zhang G, Cope GH, and El Nahas AM: Experimental diabetic renal growth: role of growth hormone and insulin-like growth factor-I. Nephrol Dial Transplant 9: 1395-1401, 1994.
120. Østerby R, Seyer-Hansen K, Gundersen HJG, and Lundbcek K: Growth hormone enhances basement membrane thickening in experimental diabetes. Diabetologia 15: 487-489, 1978.
121. Nickels DA, Maj MC, Sabnis SG, Antonovych TT, and Poth M: Effect of chronic growth hormone administration of diabetic nephropathy in the rat. Ann Clin Lab Sci 23: 462-468, 1993.
122. Seyer-Hansen K, Gundersen HJG, and Østerby R: Acute renal hypertrophy in experiment diabetes: lack of effect of short-term growth hormone administration. Diabetologia 21: 374-375, 1981.
123. Doi T, Striker LJ, Quaiffe C, Conti FG, Palmiter R, Behringer R, Brinster R, and Striker GE: Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not insulin-like growth factor-1. Am J Pathol 131: 398-403, 1988.
124. Chen N-Y, Chen WY, Bellush L, Yang C-W, Striker LJ, Striker GE, and Kopchick JJ: Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice. Endocrinology 136: 660-667, 1995.
125. Flyvbjerg A, Frystyk J, Thorlacius-Ussing O, and Orskov H: Somatostatin analogue administration prevents increase in kidney somatomedin C and initial renal growth in diabetic and uninephrectomized rats. Diabetologia 32: 261-265, 1989.
126. Flyvbjerg A, Marshall SM, Frystyk J, Hansen KW, Harris AG, and Orskov H: Octreotide administration in diabetic rats: effects on renal hypertrophy and urinary albumin excretion. Kidney Int 41: 805-812, 1992.
127. Flyvbjerg A, Frystyk J, Østerby R, and Ørskov H: Kidney IGF-I and renal hypertrophy in GH-deficient diabetic dwarf rats. Am J Physiol 262: E956-E962, 1992.
128. Flyvbjerg A, Frystyk J, Thorlacius-Ussing O, and Orskov H: Somatostatin analogue administration prevents increase in kidney somatomedin C and initial renal growth in diabetic and uninephrectomized rats. Diabetologia 32: 261-265, 1989.
129. Tannenbaum GS: Growth hormone secretory dynamics in streptozotocin diabetes: evidence of a role for exogenous circulating Somatostatin. Endocrinology 108: 76-82, 1981.
130. Press M, Tamborlane WV, Thorner MO, Vale W, Rivier J, Gertner JM, and Sherwin RS: Pituitary response to growth-hormone releasing factor in diabetes: failure of glucose-mediated suppression. Diabetes 33: 804-806, 1984.
131. Ortiz-Carro J, Gonzalez C, and Jolin T: Diurnal variations of plasma growth hormone, thyrotropin, thyroxine and triiodothyronine in streptozotocin-diabetic and food restricted rats. Endocrinology 115: 2227-2232, 1984.
132. Marshall SM, Flyvbjerg A, Frystyk J, Korsgaard L, and Ørskov H: Renal insulin-like growth factor I and growth hormone receptor binding in experimental diabetes and after unilateral nephrectomy in the rat. Diabetologia 34: 632-639, 1991.
133. Fervenza F, Tsao T, Huffman AR, Vu T, and Rabkin R: The intrarenal IGF-I axis in diabetic renal hypertrophy. J Am Soc Nephrol, 6: 766, 1995 (Abstract).
134. Fervenza F, Tsao T, and Rabkin R: Expression of the genes encoding the intrarenal IGF-I axis in established diabetic nephropathy. J Am Soc Nephrol, 6: 1040, 1995 (Abstract).
135. Bornfeldt KE, Arnqvist HJ, Enberg B, Mathews LS, and Norstedt G: Regulation of insulin-like growth factor I and growth hormone receptor gene expression by diabetes and nutritional state in rat tissues. J Endocrinol 122: 651-656, 1989.
136. Menon RK, Stephan DA, Rao RH, Shen-Orr Z, Downs LS Jr, Roberts CT Jr, LeRoith D, and Sperling MA: Tissue-specific regulation of the growth hormone receptor gene in streptozocininduced diabetes in the rat. J Endocrinol 142: 453-462, 1994.
137. Hirschberg R, Kopple JD, Blantz RC, and Tucker BJ: Effects of recombinant human insulin-like growth factor I on glomerular dynamics in the rat. J Clin Invest 87: 1200-1206, 1991.
138. Dills DG, Moss SE, Klein R, and Klein BEK: Association of elevated IGF-I levels with increased retinopathy in late-onset diabetes. Diabetes 40: 1725-1730, 1991.
139. Oemar BS, Foellmer, Hodgdon-Anandant L, and Rosenzweig SA: Regulation of insulin-like growth factor I receptors in diabetic mesangial cells. J Biol Chem 266: 2369-2373, 1991.
140. Chin E, Zhou J, and Bondy C: Anatomical relationships in the patterns of insulin-like growth factor (IGF)-I, IGF binding protein-1, and IGF-I receptor gene expression in the rat kidney. Endocrinology 130: 3237-3245, 1992.
141. Rabkin R, Brody M, Lu LH, Chan C, Shaheen, and Gillett N: Expression of genes encoding the rat renal insulin-like growth factor-I system. J Am Soc Nephrol, 6: 1511-1518, 1995.
142. Kobayashi S, Clemmons DR, and Venkatachalm MA: Colocalization of insulin-like growth factor-binding protein with insulin-like growth factor. Am J Physiol 261: F22-F28, 1991.
143. Aron DC, Rosenzweig JC, and Abboud HE: Synthesis and binding of IGF-I by human glomerular mesangial cells. J Clin Endocrin Metab 68: 585-591, 1989.
144. Rogers SA, Miller SB, and Hammerman MR: Growth hormone stimulates IGF-I gene expression in isolated rat renal collecting duct. Am J Physiol 29: F474-F479, 1990.
145. Rogers SA, Rasmussen J, Miller SB, and Hammerman MR: Insulin-like growth factor I gene expression in isolated rat collecting ducts is stimulated by epidermal growth factor. J Clin Invest 87: 347-351, 1991.
146. Kobayashi S, and Venkatachalam MA: Differential effects of calorie restriction on glomeruli and tubules of the remnant kidney. Kidney Int 42: 710-717, 1992.
147. Chin E, and Bondy C: Insulin-like growth factor system gene expression in the human kidney. J Clin Endocrinol Metab 75: 962-968, 1992.
148. Flyvbjerg A, Nielsen S, Sheikh MI, Jacobsen C, Orskob H, and Christensen El: Luminal and basolateral uptake and receptor binding of IGFI in rabbit renal proximal tubules. Am J Physiol 265: F624-633.
149. Hirschberg R, Brunori G, Kopple JD, and Guler H-P: Effects of insulin-like growth factor I on renal function in normal men. Kidney Int 43: 387-397, 1993.
150. Rogers SA, Karl IE, and Hammerman MR: Growth hormone directly stimulates gluconeogenesis in canine renal proximal tubule. Am J Physiol 257: E751-E756, 1989.
151. Quigley R, and Baum M: Effects of growth hormone and insulin-like growth factor I on rabbit proximal convoluted tubule transport. J Clin Invest 88: 368-374, 1991.
152. Jones JI, and Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16: 3-34, 1995.
153. Shimashaki S, Shimonaka M, Zhang H-P, and Ling N: Isolation and molecular characterization of three novel insulin-like growth factor binding proteins (IGFBP-4, 5 and 6). In Modern Concepts of Insulin-like Growth Factors, Spencer EM (Ed). Elsevier, New York, 1991, pp 343-358.
154. Holly JMP: Insulin-like growth factor binding proteins in diabetic and non-diabetic states. In Growth Hormone and Insulin-like Growth Factor I, Flyvbjerg A, Orskov H, and Alberti KGMM (Eds). Wiley, Chichester, 1993, pp 47-75.
155. Swisshelm K, Ryan K, Tsuchiya K, and Sager R. Enhanced expression of an insulin growth factor-like binding protein (mac 25) in senescent human mammary epithelial cells and induced expression with retinoic acid. Proc Natl Acad Sci USA 92: 4472-4476, 1995.
156. Landau D, Chin E, Bondy C, Domene H, Roberts CT Jr, Gronbaek H, Flyvbjerg A, and LeRoith D: Expression of insulin-like growth factor binding proteins in the rat kidney: effects of long-term diabetes. Endocrinology 136: 1835-1842, 1995.
157. Jones JI, D'Ercole AJ, Camacho Huber C, and Clemmons DR: Phosphorylation of IGF-binding protein I in cell culture, Proc Natl Acad Sci USA 88: 7481-7485, 1991.
158. Conover CA, Liu F, Powell D, Rosenfeld RG, and Hintz RL: IGF binding proteins from cultured human fibroblasts: characterization and hormonal regulation. J Clin Invest 83: 852-859, 1989.
159. Cohick WS, and Clemmons DR: The insulinlike growth factors. Annu Rev Physiol 55: 131-153, 1993.
160. Tsao T, Wang J, Fervenza F, Vu T, Jin HI, Hoffman AR, and Rabkin R: The intrarenal growth hormone-insulin-like growth factor-I axis in acute ischemic renal failure. Kidney Int 47: 1658-1668, 1995.
161. Hill DJ, Clemmons DR, Wilson S, Han VKM, Strain AJ, and Milner RDG: Immunological distribution of one form of IGF binding protein and IGF peptides in human fetal tissue. J Mol Endocrinol 2: 31-38, 1989.
162. Yap J, Tsao T, Stewart T, Mohler M, Cook J, and Rabkin R: Insulin-like growth factor binding protein (BP) secretion by rabbit proximal tubular cells (PRTC). J Am Soc Nephrol 3: 483, 1992 (Abstract).
163. Aron DC, Saadi HF, Nye CN, and Douglas JG: Secretion of insulin-like growth factor I and its binding proteins by collecting duct cells. Kidney Int 39: 27-32, 1991.
164. Kobayashi S, Arai T, Hishida A, and Clemmons DR: Insulin-like growth factor (IGF)-binding protein enhances the mitogenic response to IGF1 in MDCK cells. J Am Soc Nephrol 3(3): 471, 1992 (Abstract).
165. Gelato MC, Alexander D, and Marsh K: Differential tissue regulation of insulin-like growth factor binding proteins in experimental diabetes mellitus in the rat. Diabetes 41: 1511-1519, 1992.
166. Bach LA: IGF-I and IGF binding proteins in diabetes-related kidney growth. Growth Regul 2: 30-39, 1992.
167. Bang P, Brismar K, Rosenfeld RG, and Hall K: Fasting affects serum insulin-like growth factors (IGFs) and IGF-binding proteins differently in patients with noninsulin-dependent diabetes mellitus versus healthy nonobese and obese subjects. J Clin Endocrinol Metabol 78: 960-967.
168. Glaser EW, Goldstein S, and Phillips LS: Nutrition and somatomedin XVII: circulating somatomedin C during treatment of diabetic ketoacidosis. Diabetes 36: 1152-1160, 1987.
169. Rieu M, and Binoux M: Serum levels of insulinlike growth factor (IGF) and IGF binding protein in insulin-dependent diabetics during an episode of severe metabolic decompensation and the recovery phase. J Clin Endocrinol Metab 60: 781-785, 1985.
170. Graubert MD, Goldstein S, and Phillips LS: Nutrition and somatomedin. XXVII. Total and free IGF-I and IGF binding proteins in rats with streptozocin induced diabetes. Diabetes 40: 959-965, 1991.
171. Doi GT, Orlowski CC, Brown AL, Becker RE, Unterman TG, and Rechler MM: Differential tissue distribution and hormonal regulation of messenger RNAs encoding rat insulin-like growth factor-binding proteins -1 and -2. Mol Endocrinol 4: 321-328, 1990.
172. Bach LA, Cox AJ, Mendelsohn FAO, Herington AC, Werther GA, and Jerums G: Focal induction of IGF binding proteins in proximal tubules of diabetic rat kidney. Diabetes 41: 499-507, 1992.
173. Flyvbjerg A, Kessler U, Dorka B, Funk B, Ørskov H, and Kiess W: Transient increase in renal insulin-like growth factor binding proteins during initial kidney hypertrophy in experimental diabetes in rats. Diabetologia 35: 589-593, 1992.
174. Flyvbjerg A, Orskov H, Nyborg K, Frystyk J, Marshall SM, Bornfeldt KB, Arnqvist HJ, and Jorgensen KD: Kidney IGF-I accumulation occurs in four different conditions with rapid initial kidney growth in rats. In Modern Concepts of Insulin-like Growth Factors, Spencer EM (Ed). Elsevier, New York, 1991, pp 207-217.
175. Sayed-Ahmed N, Muchaneta-Kubara EC, Besbas N, Shortland J, Cope GH, and El Nahas AM: Insulin-like growth factor-I and experimental diabetic kidney disease. Exp Nephrol 1: 364-371, 1993.
176. Pedersen SB, Flyvbjerg A, and Richelsen B: Inhibition of renal ornithine decarboxylase activity prevents kidney hypertrophy in experimental diabetes. Am J Physiol 264: C453-C456, 1993.
177. Pedersen SB, Bjørn SF, Richelsen B, and Flyvjberg A: Inhibition of renal ornithine decarboxylase activity fails to reduce kidney size and urinary albumin excretion in diabetic rats with manifest kidney hypertrophy. Mol Cell Endocrinol 107: 123-128, 1995.
178. Werner H, Shen-Orr Z, Stannard B, Burguera B, Roberts CT Jr, and LeRioth D: Experimental diabetes increases insulin-like growth factor I and II receptor concentration and gene expression in kidney. Diabetes 39: 1490-1497, 1990.
179. Fagin JA, Roberts CT Jr, LeRoith D, and Brown AT: Co-ordinate decrease of tissue insulin-like growth factor I posttranscriptional alternative mRNA transcripts in diabetes mellitus. Diabetes 38: 428-434, 1989.
180. Phillip M, Werner H, Palese T, Kowarski A A, Stannard B, Bach LA, LeRoith D, and Roberts CT Jr: Differential accumulation of insulin-like growth factor-I in kidneys of pre- and postpubertal streptozotocin-diabetic rats. J Mol Endocrinol 12: 215-224, 1994.
181. Bach LA, and Jerums G: The effect of puberty on the initial renal growth and rise in insulinlike growth factor I in diabetic rats. Diabetes 39: 557-562, 1990.
182. Dahlquist G, and Rudgerg S: Microalbuminuria in diabetic children and adolescents and its relationship to puberty. Pediatr Adolesc Endocrinol 17: 153-161, 1988.
183. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, and Kahn CR: The changing natural history of nephropathy in type I diabetes. Am J Med 78: 785-794, 1985.
184. Mathiesen ER, Nexo E, Hommel E, and Parving HH: Reduced urinary excretion of epidermal growth factor in incipient and overt diabetic nephropathy. Diabetic Med 6: 121-126, 1989.
185. Cantanese VM, Sciavolino PJ, and Lango MN: Discordant, organ-specific regulation of insulinlike growth factor-I messenger ribonucleic acid in insulin deficient diabetes in rats. Endocrinology 132: 496-503, 1993.
186. Elliot SJ, Striker LJ, Hattori M, Yang CW, He CJ, Peten EP, and Striker GE: Mesangial cells from diabetic NOD mice constitutively secrete increased amounts of insulin-like growth factorI. Endocrinology 133: 1783-1788, 1993.
187. Feld SM, Hirschberg R, Artishevsky A, Nast C, and Adler SG: Insulin-like growth factor I induces proliferation and increases mRNA levels and secretion of collagen. Kidney Int 48: 52-56, 1995.
188. Watanabe Y, Makino NKH, and Kanwar YS: Modulation of glomerular proteoglycans by insulin-like growth factor-I. Kidney Int 41: 1262-1273, 1992.
189. Moran A, Borw DM, Kim Y, and Klein DJ: Effects of IGF-I and glucose on protein and proteoglycan synthesis by human fetal mesangial cells in culture. Diabetes 40: 1346-1354, 1991.
190. Bar RS, Dake BL, and Stueck S: Stimulation of proteoglycans by IGF I and II in microvessel and large vessel endothelial cells. Am J Physiol 253: E21-E27, 1987.
191. Nakamura T, Ebihara I, Fukui M, Osada S, Nagaoka I, Horikoshi S, Tomino Y, and Koide H: Messenger RNA expression for growth factors in glomeruli from focal glomerular sclerosis. Clin Immunol Immunopathol 66: 33-42, 1993.
192. Kolaczynski JW, and Caro JF: Insulin-like growth factor-1 therapy in diabetes: physiologic basis, clinical benefits and risks. Ann Intern Med 120: 47-55, 1994.
193. Flanders KC, Thompson NL, Cissel DS, Van Obberhagen-Schilling E, Baker CC, Kass ME, Ellingsworth LR, Roberts AB, and Sporn MB: Transforming growth factor-β1: histochemical localization with antibodies to different epitopes. J Cell Biol 108: 653-660, 1989.
194. Sharma K, and Ziyadeh FN: The emerging role of transforming growth factor-b in kidney diseases. Am J Physiol 266: F829-F842, 1994.
195. Roberts AB, McCune BK, and Sporn MB: TGFβ regulation of extracellular matrix. Kidney Int 41: 557-559, 1992.
196. Massague J: The transforming growth factorbeta system. Annu Rev Cell Biol 6: 597-641, 1990.
197. Choi ME, Kim EG, Huang Q, and Ballermann BJ: Rat mesangial cell hypertrophy in response to transforming growth factor-β1. Kidney Int 44: 948-958, 1993.
198. Border WA, and Noble NA: Cytokines in kidney disease: the role of transforming growth factor-β. Am J Kidney Dis 22: 105-113, 1993.
199. Wolf G, Sharma K, Chen Y, Ericksen M, and Ziyadeh FN: High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-β. Kidney Int 42: 647-656, 1992.
200. Wolf G, Mueller E, Stahl RAK, and Ziyadeh FN: Angiotensin II-induced hypertrophy of cultured murine proximal tubular cell is mediated by endogenous TGF-beta. J Clin Invest 92: 1366-1373, 1993.
201. Pankewycz OG, Guan JX, Bolton WK, Gomez A, and Benedict JF: Renal TGF-beta regulation in spontaneous diabetic NOD mice with correlations in mesangial cells. Kidney Int 46: 748-758, 1994.
202. Sharma K, Ziyadeh FN: Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am J Physiol 267: F1094-1101, 1994.
203. Shankland SJ, Scholey JW, Ly H, and Thai K: Expression of transforming growth factor-beta 1 during diabetic renal hypertrophy. Kidney Int 46: 430-442, 1994.
204. Yang C-W, Hattori M, Vlassara H, He C-J, Carome MA, Yamato E, Elliot S, Striker GE, and Striker LJ: Overexpression of transforming growth factor-β1 mRNA is associated with up- regulation of glomerular tenascin and laminin gene expression in nonobese diabetic mice. J Am Soc Nephrol 5: 1610-1617, 1995.
205. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, and Border WA: Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90: 1814-1818, 1993.
206. Kagami S, Border WA, Mille DE, and Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat mesangial cells. J Clin Invest 93: 2431-2437, 1994.
207. Shankland SJ, Ly H, Thai K, and Scholey JW: Increased glomerular capillary pressure alters glomerular cytokine expression. Circ Res 75: 884-853, 1994.
208. Okuda S, Nakamura T, Yamamoto T, Ruoslahti E, and Border WA: Dietary protein restriction rapidly reduces transforming growth factor beta 1 expression in experimental glomerulortephritis. Proc Natl Acad Sci USA 88: 9765-9769, 1991.
209. Border WA, Noble NA, Yamamoto T, Tomooka S, and Kagami S: Antagonists of transforming growth factor-beta: a novel approach to treatment of glomerulonephritis and glomerulosclerosis. Kidney Int 41: 566-570, 1992.
210. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, and Ruoslahti E: Natural inhibitor of transforming growth factor B protects against scarring in experimental kidney disease. Nature 360: 361-364, 1992.
211. Fisher DA, Salido EC, and Barajas L: Epidermal growth factor and the kidney. Annu Rev Physiol 51: 67-80, 1989.
212. Rall LB, Scott J, Bell GI, Crawford RJ, Penshow JD, Niall HD, and Coghlan JP: Mouse preproepidermal growth factor synthesis by the kidney and other tissues. Nature 313: 228-231, 1985.
213. Kajikawa K, Yasui W, Sumiyoshi H, Yoshida K, Nakayama H, Ayhan A, Yokozaki H, Ito H, and Tahara E: Expression of epidermal growth factors in human tissues. Virchows Arch (A) 418: 27-32, 1991.
214. Perheentupa J, Lakshmanan J, and Fisher DA: Epidermal growth factor in neonatal mouse urine: maturative effect of thyroxine. Pediatr Res 18: 1080-1084, 1984.
215. Rogers SA, Rasmussen J, Miller SB, and Hammerman MR: Effects of growth hormone on rat renal epidermal growth factor expression. Am J Physiol 267, F208-F214, 1994.
216. Salido EC, Yen PH, Shapiro LJ, Fisher DA, and Barajas L: In situ hybridization of preproepidermal growth factor mRNA in the mouse kidney. Am J Physiol 256: F632-F638, 1989.
217. Salido EC, Lakshmanan J, Fisher DA, Shapiro LJ, and Barajas L: Expression of epidermal growth factor in the rat kidney: an immunocytochemical and in situ hybridization study. Histochemistry 96: 65-72, 1991.
218. Jennische E, Anderson G, and Hansson HA: Epidermal growth factor is expressed by cells in the distal tubules during postnephrectomy renal growth. Acta Physiol Scand 129: 449-450, 1987.
219. Kasselberg AG, Orth DN, Gray ME, and Stahlman MT: Immunocytochemical localization of human epidermal growth factor/urogastrone in several human tissues. J Histochem Cytochem 33: 315-322, 1985.
220. Yoshioka K, Takemura T, Murakami K, Akano N, Matsubara K, Aya N, and Maki S: Identification and localization of epidermal growth factor and its receptor in the human glomerulus. Lab Invest 63: 189-196, 1990.
221. Poulsen SS, Nexø E, Olsen PS, Hess J, and Kirkegaard P: Immunohistochemical localization of epidermal growth factor in rat and man. Histochemistry 85: 389-394, 1986.
222. Gusterson BG, Cowley G, Smith JA, and Ozanne B: Cellular localization of human epidermal growth factor receptor. Cell Biol Int Rep 649-658, 1984.
223. Breyer MD, Redha R, and Breyer JA: Segmental distribution of epidermal growth factor binding sites in rabbit nephron. Am J Physiol 259: F553-F558, 1990.
224. Breyer MD, Jacobson HR, and Breyer JA: Epidermal growth factor inhibits the hydroosmotic effect of vasopressin in the isolated perfused rabbit cortical collecting tubule. J Clin Invest 82: 1313-1320, 1988.
225. Harris RC: Epidermal growth factor and transforming growth factor-alpha: new insights into cellular mechanisms and renal actions. In Contemporary Issues in Nephrology, Vol 23: Hormones, Autacoids, and the Kidney, Stein JH (Ed). 1991, pp 365-389. Churchill Livingstone Inc NY, NY.
226. Hamm LL, Hering-Smith KS, and Vehaskari VM: Epidermal growth factor and the kidney. Semin Nephrol 13: 109-115, 1993.
227. Harris RC: Response of rat inner medullary collecting duct to epidermal growth factor. Am Physiol 256: F1117, 1989.
228. Vehaskari VM, Herndon J, and Hamm LL: Mechanisms of sodium transport inhibition by epidermal growth factor in cortical collecting ducts. Am J Physiol 261: F896-F903, 1991.
229. Norman J, Badie-Dezfooly B, Nord EP, Kurtz I, Schlosser J, Chaudhari A, and Fine LG: EGF-induced mitogenesis in proximal tubular cells: potentiation by angiotensin II. Am J Physiol 253: F299-F309, 1987.
230. Humes HD, Beals TF, Cieslinski DA, Sanchez IO, and Page TP: Effects of transforming growth factor-b, transforming growth factor-a, and other growth factors on renal proximal tubule cells. Lab Invest 64: 538-545, 1991.
231. Miller SB, Rogers SA, Estes CE, and Hammerman MR: Increased distal nephron EGF content and altered distribution of peptide in compensatory renal hypertrophy. Am J Physiol 262: F1032-1038, 1992.
232. Kasayama S, Ohba Y, and Oka T: Epidermal growth factor deficiency associated with diabetes mellitus. Proc Natl Acad Sci USA 86: 7644-7648, 1989.
233. Hwang DL, and Lev-Ran A: Epidermal growth factor in serum, urine, submandibular glands and kidneys of diabetic mice. Life Sci 47: 679-685, 1990.
234. Hwang DL, Lev-Ran A, Tay YC, Chen CR, and Dev N: Epidermal growth factor excretion and receptor binding in diabetic rats. Life Sci 44: 407-416, 1989.
235. Guh J-Y, Lai Y-H, Shin S-J, Chuang L-Y, and Tsai J-H: Epidermal growth factor in renal hypertrophy in streptozotocin-diabetic rats. Nephron 59: 641-647, 1991.
236. Kashimata M, Hiramatsu M, and Minami N: Effect of streptozotocin-induced diabetes on epidermal growth factor receptors in rat liver plasma membrane. Biochim Biophys Acta 923: 496-500, 1987.
237. Ito J, Kamiya Y, and Kawaguchi M: Increased content of epidermal growth factor in platelet lysates in non-insulin-dependent diabetes mellitus. Life Sci 53: 717-724, 1993.
238. Kawaguchi M, Kamiya Y, Ito J, Fuji T, Hayakawa F, Sakuma N, and Fujinami T: Excretion of urinary epidermal growth factor in non-insulin dependent diabetes mellitus. Life Sci 52: 1181-1186, 1993.
239. ter Meulen CG, Biol HJ, van Kamp GJ, Gans RO, and Donker AJ: Urinary epidermal growth factor excretion is correlated to renal function loss per se and not to the degree of diabetic renal failure. Neth J Med 44: 12-17, 1994.
240. Mathiesen ER, Saurbrey N, Hommel E, and Parving HH: Microalbuminuria in children with insulin-dependent diabetes melliltus. Pediatr Adolesc Endocrinol 17: 162-165, 1988.
241. Mattila A-L, Pasternack A, Viinikka L, and Perheentupa J: Subnormal concentrations of urinary epidermal growth factor in patients with kidney disease. J Clin Endocrinol Metabol 62: 1180-1183, 1986.
242. Okamoto M, Kahn CR, Maron R, and White ME: Decreased autophosphorylation of EGF receptor in insulin-deficient diabetic rats. Am J Physiol 254: E429-E434, 1988.
243. De Diego JG, Rouille DG, Gorden P, and Carpenter J-L: Epidermal growth factor receptor internalization and biosynthesis in the diabetic rat. Exp Cell Res 200: 77-82, 1992.
244. Shigeki H, Abraham JA, Miller J, Fiddes JC, and Klagsbrun M: A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 51: 936-939, 1991.
245. Tan M-S, Tsai J-C, Lee Y-J, Chen H-C, Shin SJ, lay Y-H, Perrella MA, Bianchi C, Higashiyama B, Endege W, Lee M-E, and Tsai J-H: Induction of heparin-binding epidermal growth factor-like growth factor mRNA by protein kinase C activators. Kidney Int 46: 690-695, 1994.
246. Lee Y-J, Shin S-J, Lin S-R, Tan M-S, and Tsai J-H: Increased expression of heparin binding epidermal-growth-factor-like growth factor mRNA in the kidney of streptozotocin-induced diabetic rats. Biochem Biophys Res Commun 207: 216-222, 1995.
247. Daniel TO, and Kumjian DA: Platelet-derived growth factor in renal development and disease. Semin Nephrol 13: 87-95, 1993.
248. Ross R, Raines EW, and Bowen-Pope DF: The biology of platelet-derived growth factor. Cell 46: 155-169, 1986.
249. Ross R, Bowen-Pope DF, and Raines EW: Platelet-derived growth factor and its role in health and disease. Phil Trans R Soc Lond B 327: 155-169, 1990.
250. Floege J, Eng E, Young BA, Alpers CE, Barrett TB, Bowen-Pope DF, and Johnson RJ: Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats. J Clin Invest 92: 2952-2962, 1993.
251. Pierce GF, Vande-Berg J, and Rudolph R: Platelet-derived growth factor-BB and transforming growth factor beta 1 selectively modulate glycosaminoglycans, collagen, and myofibroblasts in excisional wounds. Am J Pathol 138: 629-646, 1991.
252. Lovett DH, Ryan JL, and Sterzel RB: Stimulation of rat mesangial cell proliferation by macrophage Interleukin 1. J Immunol 131: 2830-2836, 1983.
253. Johnson RJ, Floege WG, Couser WG, and Alpers CE: Role of platelet-derived growth factor in glomerular disease. J Am Soc Nephrol 4: 119-128, 1993.
254. Mikhail N, Fukuda N, Tremblay J, and Hamet P: Platelets, growth factors, and vascular smooth-muscle cells in hypertension and diabetes. J Cardiovasc Pharmacol 22: S64-S74, 1993.
255. Fukui M, Nakamura T, Ebihara I, Makita Y, Osada S, Tomino Y, and Koide H: Effects of enalapril on endothelin-1 and growth factor gene expression in diabetic rat glomeruli. J Lab Clin Med 123: 763-768, 1994.
256. Frank RN: Vascular endothelial growth factor: its role in retinal vascular proliferation: N Engl J Med 331: 1519-1520, 1994.
257. Waldbillig RJ, Jones BE, Schoen TJ, Moshayedi P, Heidersbach S, Bitar MS, van Kuijk FJGM, de Juan E, Kador P, and Chader GJ: Vitreal insulin-like growth factor binding proteins (IGFBPs) are increased in human and animal diabetics. Curr Eye Res 13: 539-546, 1994.
258. Grant MB, Marnes RN, Fitzgerald C, Ellis EA, Aboufriekha M, and Guy J: Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia 36: 282-291, 1993.
259. Sivalingam A, Kenney J, Brown GC, Benson WE, and Donoso L: Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol 108: 869-872, 1990.
260. Aiello LP, Avey RL, Arrigg PG et al: Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487, 1994.
261. Thieme H, Aiello LP, Takagi H, Ferrara N, and King GL: Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes 44: 98-103, 1995.
262. Merimee TJ, Zapf J, and Froesch ER: Insulinlike growth factors: studies in diabetics with and without retinopathy. N Engl J Med 309: 527-530, 1983.
263. Hyer SL, Sharp PS, Brooks RA, Burrin JM, and Kohner EM: Serum IGF-I concentration in diabetic retinopathy. Diabetic Med 5: 356-360, 1988.
264. Nardelli GM, Guarstamacchia E, DiPaolo S, Balice A, Rosco M, Santoro G, Lollino G, and Giorgino R: Somatomedin-C (Sm-C): study in diabetic patients with and without retinopathy. Acta Diabetol Lat 26: 217-224, 1989.
265. Wang Q, Dills DG, Klein R, Klein BEK, and Moss SE: Does insulin-like growth factor I predict incidence and progression of diabetic retinopathy? Diabetes 44: 161-164, 1995.
266. Karpen CW, Spanheimer RG, Randolph AL, and Lowe WL Jr: Tissue-specific regulation of basic fibroblast growth factor mRNA levels by diabetes. Diabetes 41: 222-226, 1992.
267. Minchenko A, Bauer T, Salceda S, and Caro J: Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab Invest 71: 374-379, 1994.
268. Baynes JW: AGEing growth factors: a role in diabetic vascular disease. J Clin Invest 94: 2, 1994.
269. Sharma K, Jin Y, Guo J, and Ziyadeh FN: Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45: 522-530, 1996.